Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Carlo M, Giri V, Paller C, Abida W, Alumkal J, Beer T, Beltran H, George D, Heath E, Higano C, McKay R, Morgans A, Patnaik A, Ryan C, Schaeffer E, Stadler W, Taplin M, Kauff N, Vinson J, Antonarakis E, Cheng H. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology 2018, 2018: 1-14. PMID: 30761386, PMCID: PMC6370313, DOI: 10.1200/po.18.00060.Peer-Reviewed Original ResearchGermline genetic testingProstate cancerGenetic testingAdvanced diseaseClinical trialsTreatment selectionProstate Cancer Clinical Trials ConsortiumClinical trial eligibility determinationCascade testingClinical Trials ConsortiumTherapeutic clinical trialsGenetic counselingClinical trial purposesTumor genomic profilingPost-test genetic counselingCancer risk assessmentDNA damage repair genesAppropriate genetic counselingTreatment response predictionWorking GroupClinical benefitPrompt testingCancer screeningGenetic testing practicesTreatment decisions